← Siemens Healthineers overview

Siemens Healthineers vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Siemens Healthineers AG (SHL.XETRA)

Q3 2026
▲3

Siemens Healthineers: profit outlook raised, revenue trimmed, new deals build demand

  • Profit guidance raised, revenue growth cut Siemens Healthineers raised its fiscal 2026 earnings per share forecast to €2.35–2.45 but lowered comparable revenue growth to 3.5–4.0%. Profit is improving, but slower sales growth and tariff/pricing pressures keep a lid on the stock.

    This is the single biggest company-specific event of the period and directly explains the mixed share price reaction.

  • New partnerships expand cancer and liver diagnostics Siemens Healthineers teamed up with Novo on non-invasive liver diagnostics and with Thailand's PRINC on advanced cancer care, including radiotherapy equipment. These deals open recurring revenue streams and embed its tools in more hospitals.

    Fresh commercial wins show real demand for its products and support future revenue growth.

  • Surveys and reports point to strong lab and imaging demand A Siemens Healthineers survey found 54% of U.S. healthcare executives prioritize lab equipment upgrades, and a company report highlighted stroke care gaps in Southeast Asia. Both signal growing demand for its diagnostic and imaging solutions.

    These demand indicators support the bull case for Siemens Healthineers' core segments.

  • AI imaging and MRI markets forecast to grow strongly Industry reports project the AI medical imaging market will reach $19.4 billion by 2035 and the MRI systems market $9.68 billion by 2031, with Siemens Healthineers named a key player. This supports long-term demand for its imaging and AI products.

    Market growth forecasts reinforce the structural growth story behind the stock.

August 2026
▲3

Siemens Healthineers: profit outlook raised, revenue trimmed, new deals build demand

  • Profit guidance raised, revenue growth cut Siemens Healthineers raised its fiscal 2026 earnings per share forecast to €2.35–2.45 but lowered comparable revenue growth to 3.5–4.0%. Profit is improving, but slower sales growth and tariff/pricing pressures keep a lid on the stock.

    This is the single biggest company-specific event of the period and directly explains the mixed share price reaction.

  • New partnerships expand cancer and liver diagnostics Siemens Healthineers teamed up with Novo on non-invasive liver diagnostics and with Thailand's PRINC on advanced cancer care, including radiotherapy equipment. These deals open recurring revenue streams and embed its tools in more hospitals.

    Fresh commercial wins show real demand for its products and support future revenue growth.

  • Surveys and reports point to strong lab and imaging demand A Siemens Healthineers survey found 54% of U.S. healthcare executives prioritize lab equipment upgrades, and a company report highlighted stroke care gaps in Southeast Asia. Both signal growing demand for its diagnostic and imaging solutions.

    These demand indicators support the bull case for Siemens Healthineers' core segments.

  • AI imaging and MRI markets forecast to grow strongly Industry reports project the AI medical imaging market will reach $19.4 billion by 2035 and the MRI systems market $9.68 billion by 2031, with Siemens Healthineers named a key player. This supports long-term demand for its imaging and AI products.

    Market growth forecasts reinforce the structural growth story behind the stock.

Latest
▲3

Siemens Healthineers: profit outlook raised, revenue trimmed, new deals build demand

  • Profit guidance raised, revenue growth cut Siemens Healthineers raised its fiscal 2026 earnings per share forecast to €2.35–2.45 but lowered comparable revenue growth to 3.5–4.0%. Profit is improving, but slower sales growth and tariff/pricing pressures keep a lid on the stock.

    This is the single biggest company-specific event of the period and directly explains the mixed share price reaction.

  • New partnerships expand cancer and liver diagnostics Siemens Healthineers teamed up with Novo on non-invasive liver diagnostics and with Thailand's PRINC on advanced cancer care, including radiotherapy equipment. These deals open recurring revenue streams and embed its tools in more hospitals.

    Fresh commercial wins show real demand for its products and support future revenue growth.

  • Surveys and reports point to strong lab and imaging demand A Siemens Healthineers survey found 54% of U.S. healthcare executives prioritize lab equipment upgrades, and a company report highlighted stroke care gaps in Southeast Asia. Both signal growing demand for its diagnostic and imaging solutions.

    These demand indicators support the bull case for Siemens Healthineers' core segments.

  • AI imaging and MRI markets forecast to grow strongly Industry reports project the AI medical imaging market will reach $19.4 billion by 2035 and the MRI systems market $9.68 billion by 2031, with Siemens Healthineers named a key player. This supports long-term demand for its imaging and AI products.

    Market growth forecasts reinforce the structural growth story behind the stock.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.